前列腺癌病人共病及其管理的研究现状
摘要
就国外对前列腺癌病人共病的研究现状、特点、危害以及如何对前列腺癌病人共病更加科学的管理进行综述,为我国前列腺癌病人共病的管理提供依据。
引文
[1]FEINSTEIN A R.The pre-therapeutic classification of co-morbidity in chronic disease[J].J Chronic Dis,1970,23(7):455-468.
[2]李苏宜,沈干.肿瘤患者“共病”[J].中国临床保健杂志,2016,19(5):449-450.
[3]Siegel R L,Miller K D,Jemal A.Cancer statistics[J].CA Cancer JClin,2017,67(1):7-30.
[4]吴楠,马志方.前列腺癌内分泌治疗后认知功能障碍的研究进展[J].现代泌尿外科杂志,2016,21(10):811-813.
[5]HOLZBEIERLEIN J M,CASTLE E,THRASHER J B.Complications of androgen deprivation therapy:prevention and treatment[J].Oncology(Williston Park),2004,18(3):303-321.
[6]AHMADI H,DANESHMAND S.Androgen deprivation therapy:evidence-based management of side effects[J].BJU Int,2013,111(4):543-548.
[7]VAN DEN BUSSCHE H,KOLLER D,KOLONKO T,et al.Which chronic diseases and disease combinations are specific to multimorbidity in the elderly?Results of a claims data based cross-sectional study in Germany[J].BMC Public Health,2011,11:101.
[8]NGUYEN-NIELSEN M,NORGAARD M,JACOBSEN J B,et al.Comorbidity and survival of Danish prostate cancer patients from2000-2011:apopulation-based cohort study[J].Clin Epidemiol,2013,5(Suppl 1):47-55.
[9]DASKIVICH T J,FAN K H,KOYAMA T,et al.Effect of age,tumor risk,and comorbidity on competing risks for survival in a U.S.population-based cohort of men with prostate cancer[J].Ann Intern Med,2013,158(10):709-717.
[10]EPSTEIN M M,EDGREN G,RIDER J R,et al.Temporal trends in cause of death among Swedish and US men with prostate cancer[J].J Natl Cancer Inst,2012,104(17):1335-1342.
[11]BERGLUND A,GARMO H,TISHELMAN C,et al.Comorbidity,treatment and mortality:apopulation based cohort study of prostate cancer in PCBaSe Sweden[J].J Urol,2011,185(3):833-839.
[12]REEVE B B,CHEN R C,MOORE D T,et al.Impact of comorbidity on health-related quality of life after prostate cancer treatment:combined analysis of two prospective cohort studies[J].BJU Int,2014,114(6b):E74-E81.
[13]DASKIVICH T J,CHAMIE K,KWAN L,et al.Comorbidity and competing risks for mortality in men with prostate cancer[J].Cancer,2011,117(20):4642-4650.
[14]NUTZEL A,DAHLHAUS A,FUCHS A,et al.Self-rated health in multimorbid older general practice patients:a crosssectional study in Germany[J].BMC Fam Pract,2014,15:1.
[15]ORDING A G,HORVATH-PUHO E,LASH T L,et al.Prostate cancer,comorbidity,and the risk of venous thromboembolism:a cohort study of 44,035Danish prostate cancer patients,1995-2011[J].Cancer,2015,121(20):3692-3699.
[16]Guiding principles for the care of older adults with multimorbidity:an approach for clinicians:American geriatrics society expert panel on the care of older adults with multimorbidity[J].J Am Geriatr Soc,2012,60(10):E1-E25.
[2]李苏宜,沈干.肿瘤患者“共病”[J].中国临床保健杂志,2016,19(5):449-450.
[3]Siegel R L,Miller K D,Jemal A.Cancer statistics[J].CA Cancer JClin,2017,67(1):7-30.
[4]吴楠,马志方.前列腺癌内分泌治疗后认知功能障碍的研究进展[J].现代泌尿外科杂志,2016,21(10):811-813.
[5]HOLZBEIERLEIN J M,CASTLE E,THRASHER J B.Complications of androgen deprivation therapy:prevention and treatment[J].Oncology(Williston Park),2004,18(3):303-321.
[6]AHMADI H,DANESHMAND S.Androgen deprivation therapy:evidence-based management of side effects[J].BJU Int,2013,111(4):543-548.
[7]VAN DEN BUSSCHE H,KOLLER D,KOLONKO T,et al.Which chronic diseases and disease combinations are specific to multimorbidity in the elderly?Results of a claims data based cross-sectional study in Germany[J].BMC Public Health,2011,11:101.
[8]NGUYEN-NIELSEN M,NORGAARD M,JACOBSEN J B,et al.Comorbidity and survival of Danish prostate cancer patients from2000-2011:apopulation-based cohort study[J].Clin Epidemiol,2013,5(Suppl 1):47-55.
[9]DASKIVICH T J,FAN K H,KOYAMA T,et al.Effect of age,tumor risk,and comorbidity on competing risks for survival in a U.S.population-based cohort of men with prostate cancer[J].Ann Intern Med,2013,158(10):709-717.
[10]EPSTEIN M M,EDGREN G,RIDER J R,et al.Temporal trends in cause of death among Swedish and US men with prostate cancer[J].J Natl Cancer Inst,2012,104(17):1335-1342.
[11]BERGLUND A,GARMO H,TISHELMAN C,et al.Comorbidity,treatment and mortality:apopulation based cohort study of prostate cancer in PCBaSe Sweden[J].J Urol,2011,185(3):833-839.
[12]REEVE B B,CHEN R C,MOORE D T,et al.Impact of comorbidity on health-related quality of life after prostate cancer treatment:combined analysis of two prospective cohort studies[J].BJU Int,2014,114(6b):E74-E81.
[13]DASKIVICH T J,CHAMIE K,KWAN L,et al.Comorbidity and competing risks for mortality in men with prostate cancer[J].Cancer,2011,117(20):4642-4650.
[14]NUTZEL A,DAHLHAUS A,FUCHS A,et al.Self-rated health in multimorbid older general practice patients:a crosssectional study in Germany[J].BMC Fam Pract,2014,15:1.
[15]ORDING A G,HORVATH-PUHO E,LASH T L,et al.Prostate cancer,comorbidity,and the risk of venous thromboembolism:a cohort study of 44,035Danish prostate cancer patients,1995-2011[J].Cancer,2015,121(20):3692-3699.
[16]Guiding principles for the care of older adults with multimorbidity:an approach for clinicians:American geriatrics society expert panel on the care of older adults with multimorbidity[J].J Am Geriatr Soc,2012,60(10):E1-E25.